Skip to content

Author

Qing-Qing Xu

We have 3 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Carbon monoxide-releasing mesoporous polydopamine nanoplatform for lysosomal disruption and synergistic tumor therapy.

Lysosomes, pivotal in tumor progression and therapy resistance, sustain cancer survival through drug tolerance and stress adaptation. Conventional lysosome-disrupting approaches faced transient efficacy from poor targeting or cellular repair mechanisms. To address this, we engineered a biomimetic nanoplatform (FeCO@MP-...

Shuai-Peng Feng, Lu-Ping Sha, Zi-Wei Yan et al. · 0 citations
Sep 2026

Targeting Tumor–CAFs Crosstalk to Reverse Drug Resistance and Immunosuppression Through Cuproptosis

Chemotherapy resistance and immunosuppression are the current key bottlenecks in tumor treatment. In the tumor microenvironment (TME), cancer‐associated fibroblasts (CAFs) secrete dense extracellular matrix and various immunosuppressive factors, forming a dynamic “tumor–CAFs crosstalk”, which drives the progression o...

Qing-Qing Xu, Shuai-Peng Feng, Dong-Lin Bian et al. · 0 citations
Aug 2026

Copper/tetrasulfide co-doped mesoporous organosilica for multimodal imaging-guided photothermal tumor stiffness modulation and synergistic chemo-chemodynamic therapy of triple-negative breast cancer.

Overall, DCMP provides a multimodal imaging-guided nanotherapeutic strategy that combines chemical tumor killing with physical tumor matrix modulation to enhance chemo-chemodynamic-photothermal antitumor therapy.

Long Wan, Lu Zou, Dong-Lin Bian et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.